Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Evaluation of the safety and efficacy of m-beam and m-beac due to the shortage supply of melphalan

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: MIYAGAWA, Keiko (Kameda Medical Center)
  • Co-author(s): Keiko Miyagawa: Pharmacy, Kameda Medical Center, Kamogawa, Japan
    Yusuke Nakagawa: Pharmacy, Kameda Medical Center, Kamogawa, Japan
    Tatsuya Isezaki: Pharmacy, Kameda Medical Center, Kamogawa, Japan
    Koji Masuda
    Osamu Yasumuro: Pharmacy, Kameda Medical Center, Kamogawa, Japan
    Ryohkan Funakoshi: Pharmacy, Kameda Medical Center, Kamogawa, Japan
    Kosei Matsue: Hematology, Kameda Medical Center, Kamogawa, Japan
  • Abstract:

    Background

    Melphalan IV (Mel) distribution has been suspended globally due to manufacturing process difficulties occurring in November 2015. We have been using the combination of Ranimustine/Etoposide/Cytarabine/Cyclophosphamide (M-BEAC) as pretreatment for autologous stem-cell transplantation (ASCT) instead of..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses